Trial Profile
Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2023
Price :
$35
*
At a glance
- Drugs GSK 4069327A (Primary)
- Indications Bacillary dysentery
- Focus Pharmacodynamics; Proof of concept
- Sponsors LimmaTech Biologics
- 09 Oct 2023 According to a -LimmaTech Biologics AG media release, the company expects to announce preliminary results from this clinical trial in the second half of 2023.
- 23 Aug 2017 Status changed from active, no longer recruiting to completed.
- 21 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Aug 2017.